Full Press Release Details
Ascentage Pharma to Participate in Three Upcoming
Investor Conferences in September 2025
ROCKVILLE, Md. and SUZHOU, China, August 25, 2025
-- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company"),
a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel,
differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in the
following investor conferences in September 2025.
The live webcast of the Citi and Cantor events
can be accessed from the investors section of the Company's website at https://ir.ascentage.com/news-events/events. An archived
replay will be available for 30 days following the event.
About Ascentage Pharma Group International
Ascentage Pharma Group International (NASDAQ:
AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company") is a global, commercial stage, integrated
biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet
medical needs in cancer. The company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting
key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The Company's first approved product, Olverembatinib,
is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP)
with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and
second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an
FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for
patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company's second approved product, Lisaftoclax,
is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China's National
Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) who have previously received at least one systemic therapy including Bruton's tyrosine kinase (BTK) inhibitors. The Company
is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK
inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2
study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared
GLORA-4 study in patients with newly diagnosed HR MDS.
Leveraging its robust R&D capabilities, Ascentage
Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with
numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to
research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National
Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained
in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations,
beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with
the SEC, including those set forth in the sections titled "Risk factors" and "Cautionary note regarding forward-looking
statements" in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections
headed "Forward-looking Statements" and "Risk Factors" in the prospectus of the Company for its Hong Kong initial
public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited it has made or it
makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from
the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release
do not constitute profit forecast by the Company's management.
As a result of these factors, you should not rely
on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are
based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak
only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Hogan Wan, Head of IR and Strategy
Stephanie Carrington